Small Molecule Epigenetic Inhibitors – 2021
EEpigenetics is a branch of genetics that studies the heritable changes of gene expression without changing the nucleotide sequence of...
Kinase Inhibitors in Preclinical Development – 2021
First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration...
Kinase Inhibitors in Clinical Development – 2021
First cancer targeting tyrosine kinase inhibitor imatinib was approved to enter the market by the US Food and Drug Administration...
Targeted Cancer Therapies – Small Molecules
Small Molecule drug treatment is one of the main approaches in treating cancer. Until recent years, chemotherapy was the only...
Clinical Stage Antibody Drug Conjugates in Active Development – 2021
109 Antibody Drug Conjugates Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
Pre-Clinical Stage Antibody Drug Conjugates in Active Development – 2021
90 Antibody Drug Conjugates Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
Preclinical Stage Bispecific Antibodies in Active Development – 2021
90 Bi-specific Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
Clinical Stage Bispecific Antibodies in Active Development – 2021
109 Bi-specific Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
Pre-Clinical Stage Monoclonal Antibodies in Active Development – 2021
Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.
Clinical Stage Monoclonal Antibodies in Active Development – 2021
Monoclonal Antibody Name, Target, Developer, Partner, Highest Phase of Development, NCT Number, Cancer Indications etc.